We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · March 30, 2021

Combination Therapies for Bridging Fibrosis and Cirrhosis Attributable to NASH

Hepatology (Baltimore, Md.)


Additional Info

Hepatology (Baltimore, Md.)
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
Hepatology 2021 Feb 01;73(2)625-643, R Loomba, M Noureddin, KV Kowdley, A Kohli, A Sheikh, G Neff, BR Bhandari, N Gunn, SH Caldwell, Z Goodman, I Wapinski, M Resnick, AH Beck, D Ding, C Jia, JC Chuang, RS Huss, C Chung, GM Subramanian, RP Myers, K Patel, BB Borg, R Ghalib, H Kabler, J Poulos, Z Younes, M Elkhashab, T Hassanein, R Iyer, P Ruane, ML Shiffman, S Strasser, VW Wong, N Alkhouri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading